Impact of Edaravone on Short‐Term and Long‐Term Motor Recovery After Acute Ischemic Stroke in Patients Who Did Not Receive Thrombolytic or Endovascular Treatment.
Saved in:
| Title: | Impact of Edaravone on Short‐Term and Long‐Term Motor Recovery After Acute Ischemic Stroke in Patients Who Did Not Receive Thrombolytic or Endovascular Treatment. |
|---|---|
| Authors: | Kazemloo, Mehdi (AUTHOR), Shamlouie, Fatemeh (AUTHOR), Ebrahimi Nejad, Majid (AUTHOR), Hosseini Nejad Mir, Nahid (AUTHOR), Yarahmadi, Danyal (AUTHOR), Subramanian, Senthilkumar (AUTHOR) |
| Source: | Acta Neurologica Scandinavica. 6/10/2026, Vol. 2026, p1-6. 6p. |
| Subjects: | Ischemic stroke, Therapeutics, Free radical scavengers, Cohort analysis, Medical rehabilitation, Stroke rehabilitation, Intravenous therapy, Motor ability testing |
| Abstract: | Background: Many patients with acute ischemic stroke (AIS) are ineligible for thrombolysis. Evidence on edaravone in this population is limited. Methods: This study is a retrospective cohort study on adults with imaging‐confirmed AIS admitted to Shohada‐e‐Ashayer Hospital (March 2022–February 2023) who did not receive thrombolysis. Patients who received intravenous edaravone within the first day of onset plus standard care were compared with standard care alone. Motor strength was assessed with the Medical Research Council (MRC) scale (0–5) at baseline, 1 week, and 3 months. The primary outcome was 3‐month motor function; secondary outcomes included ≥ 2‐point improvement from baseline. Result: Among 160 patients (n = 80 edaravone; n = 80 control), baseline characteristics were similar. At 3 months, the intervention group had higher MRC grades and a higher proportion achieving ≥ 2‐grade improvement; 1‐week differences were not significant. Conclusions: In AIS patients ineligible for thrombolysis, edaravone was associated with better 3‐month motor strength; no significant between‐group differences were observed at 1 week. Prospective randomized trials are warranted. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Many patients with acute ischemic stroke (AIS) are ineligible for thrombolysis. Evidence on edaravone in this population is limited. Methods: This study is a retrospective cohort study on adults with imaging‐confirmed AIS admitted to Shohada‐e‐Ashayer Hospital (March 2022–February 2023) who did not receive thrombolysis. Patients who received intravenous edaravone within the first day of onset plus standard care were compared with standard care alone. Motor strength was assessed with the Medical Research Council (MRC) scale (0–5) at baseline, 1 week, and 3 months. The primary outcome was 3‐month motor function; secondary outcomes included ≥ 2‐point improvement from baseline. Result: Among 160 patients (n = 80 edaravone; n = 80 control), baseline characteristics were similar. At 3 months, the intervention group had higher MRC grades and a higher proportion achieving ≥ 2‐grade improvement; 1‐week differences were not significant. Conclusions: In AIS patients ineligible for thrombolysis, edaravone was associated with better 3‐month motor strength; no significant between‐group differences were observed at 1 week. Prospective randomized trials are warranted. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00016314 |
| DOI: | 10.1155/ane/5558787 |
